Johnson & Johnson agreed on 28 July 2026 to a $5.5 billion settlement to resolve approximately 69,000 US lawsuits consolidated in federal court in New Jersey, alleging that its talc-based baby powder and related products caused ovarian cancer [Brief - 2026-07-29]. This represents a significant legal development for the company, which has faced talc-related litigation for a number of years. No other healthcare-specific macro briefings were published in the relevant period; broader market coverage focused on semiconductor sector volatility and energy price movements tied to Middle East supply dynamics [Brief - 2026-07-15].
For the trailing twelve months ending 28 June 2026, Johnson & Johnson recorded revenue of $97.93 billion, reflecting year-over-year growth of 6.60%. Net income over the same period stood at $21.04 billion, producing a net margin of 21.48%. Gross margin was reported at 67.91% and operating margin at 27.37%. Earnings per share declined 0.87% year-over-year. The company held $20.42 billion in cash against total debt of $49.04 billion. The price-to-earnings ratio stood at 30.11 [SEC 10-Q - JNJ - 2026-06-28].
Insider activity was the primary trigger for this report. Eight transactions were recorded in August 2026, with a net direction of selling and a combined net value of approximately -$22.4 million [SEC Form 4 - JNJ - 2026-08]. No institutional 13F filing data was available for inclusion in this report.
The prevailing macro backdrop features a 10-year US Treasury yield of 4.69% and a 2-year yield of 4.25%, producing a normal yield curve configuration [FRED DGS10] [FRED DGS2]. The spread between the two tenors stood at 44 basis points at the time of report generation, reflecting a modestly upward-sloping term structure across the rate environment in which JNJ operates.